William Blair analyst Matt Larew has maintained their bullish stance on OPCH stock, giving a Buy rating on July 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Buy rating due to a combination of factors including Option Care Health’s strong financial performance and positive outlook. The company reported a significant 15.4% year-over-year increase in net revenue for the second quarter, surpassing both the firm’s and consensus estimates. Additionally, the adjusted EBITDA and EPS also exceeded expectations, indicating robust operational efficiency and profitability.
Moreover, Option Care Health has consistently delivered results above expectations for 22 consecutive quarters, showcasing its resilience and growth potential despite challenges such as the Stelara headwinds. The company has also raised its full-year guidance for revenue, adjusted EBITDA, and EPS, reflecting confidence in its future performance. These factors, combined with strategic acquisitions and market share gains, contribute to the positive outlook and justify the Buy rating.
In another report released on July 25, Citizens JMP also reiterated a Buy rating on the stock with a $36.00 price target.